Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
2023年半年度非经营性资金占用及其他关联资金往来情况表
Interim / Quarterly Report Classification · 95% confidence The document is a summary table of non-operating fund occupation and other related party fund transactions for the half-year period of 2023. It contains detailed financial data such as balances, amounts, and interest related to these transactions. The document is relatively short (2326 characters) and focuses on financial data for a half-year period, indicating it is a financial report for an interim period. It is not an announcement or a certification but contains substantive financial data and analysis for the half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-18 Chinese
关于2020年限制性股票激励计划预留授予的第三个解除限售期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the achievement of conditions for the third release of restricted stock under a 2020 stock incentive plan. It details the number of shares unlocked, the performance conditions met, board and supervisory approvals, and legal opinions. The content focuses on stock incentive plan updates, share unlocking, and related corporate governance matters. It is not a full financial report, earnings release, or regulatory filing about financial results. It is also not a proxy statement or voting result announcement. The document is a formal announcement about the stock incentive plan's progress and share unlocking events, which fits best under the category of Capital/Financing Update (CAP), as it relates to changes in share capital availability and stock incentives.
2023-08-18 Chinese
2023年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年半年度募集资金存放与使用情况专项报告" which translates to "2023 Half-Year Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their storage, usage, changes in investment projects, and compliance with regulatory requirements. The document includes financial figures related to fundraising and usage for the half-year period ending June 30, 2023. It is a specialized report focused on the management and use of capital raised by the company, not a general financial report like an annual or interim report. It is not an announcement of a report but the report itself, given the length (7029 characters) and detailed financial data. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-08-18 Chinese
独立董事关于第五届董事会第十八次会议审议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding matters reviewed at the 18th meeting of the 5th board of directors. It covers topics such as the company's external guarantees, use of raised funds in the first half of 2023, appointment of senior management, stock incentive plan conditions, and stock repurchase and cancellation. The document references compliance with laws and regulations, board meeting resolutions, and provides detailed opinions on these governance and management matters. It is not a full financial report, earnings release, or audit report, but rather a formal board/management related announcement concerning governance and management decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3045 characters, which is consistent with a detailed board opinion rather than a full report or announcement of a report.
2023-08-18 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding decisions made at the 18th meeting of the 5th board. It includes approvals of various proposals such as the 2023 semi-annual report, acquisition plans, senior management appointments, stock incentive plans, and stock repurchase. The document does not contain the actual semi-annual report or detailed financial statements but references other announcements where those reports are published. The document is primarily about board meeting resolutions and management changes, including appointments of senior management. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is an announcement of decisions rather than a full report, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-08-18 Chinese
监事会关于2020年限制性股票激励计划预留授予的第三个解除限售期解除限售激励对象名单的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board opinion on the verification of the list of incentive recipients for the third release period of a 2020 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and confirms the legality and validity of the release of stock restrictions. The document is short (1150 characters) and does not contain financial statements or detailed financial data. It is a formal verification or opinion related to a stock incentive plan, not a full report or announcement of voting results. It fits best under Regulatory Filings (RNS) as it is a compliance and verification document related to corporate governance and stock incentive plans but does not match other more specific categories like Remuneration Information or Share Issue/Capital Change. Therefore, the classification is RNS with high confidence.
2023-08-18 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.